Follow the people · Insider
Daniel S. Lorrain
Daniel S. Lorrain files insider transactions with the SEC as a chief scientific officer of Contineum Therapeutics (CTNM). We hold 14 disclosed purchases and sales filed since 29 May 2024, 4 of them in the last 90 days.
- Files forCTNM
- Disclosed buys and sells14 in all, 4 in the last 90 days
- Last disclosure10 July 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 24 May 2024 — 9 July 2026Chief Scientific Officer · Contineum Therapeutics (CTNM)63 Form 4 lines · source: SEC Form 4
Everything they disclosed
63 entries, newest first — one per disclosure report, one per Form 4 line- exercised options over 1,015 shares of Contineum TherapeuticsSEC Form 410 July 2026Class A Common Stock · traded 8 July 2026 · filed 10 July 2026
- ▼ sold on the open market 1,015 shares of Contineum TherapeuticsSEC Form 410 July 2026Class A Common Stock · traded 8 July 2026 · filed 10 July 2026
- exercised options over 25 shares of Contineum TherapeuticsSEC Form 410 July 2026Class A Common Stock · traded 9 July 2026 · filed 10 July 2026
- ▼ sold on the open market 25 shares of Contineum TherapeuticsSEC Form 410 July 2026Class A Common Stock · traded 9 July 2026 · filed 10 July 2026
- exercised options over 1,015 shares of Contineum Therapeutics (a derivative holding)SEC Form 410 July 2026Stock Option (right to buy) · traded 8 July 2026 · filed 10 July 2026
- exercised options over 25 shares of Contineum Therapeutics (a derivative holding)SEC Form 410 July 2026Stock Option (right to buy) · traded 9 July 2026 · filed 10 July 2026
- exercised options over 28,826 shares of Contineum TherapeuticsSEC Form 42 July 2026Class A Common Stock · traded 30 June 2026 · filed 2 July 2026
- ▼ sold on the open market 28,826 shares of Contineum TherapeuticsSEC Form 42 July 2026Class A Common Stock · traded 30 June 2026 · filed 2 July 2026
- exercised options over 4,183 shares of Contineum TherapeuticsSEC Form 42 July 2026Class A Common Stock · traded 1 July 2026 · filed 2 July 2026
- ▼ sold on the open market 5,852 shares of Contineum TherapeuticsSEC Form 42 July 2026Class A Common Stock · traded 1 July 2026 · filed 2 July 2026
- ▼ sold on the open market 2,501 shares of Contineum TherapeuticsSEC Form 42 July 2026Class A Common Stock · traded 1 July 2026 · filed 2 July 2026
- exercised options over 28,826 shares of Contineum Therapeutics (a derivative holding)SEC Form 42 July 2026Stock Option (right to buy) · traded 30 June 2026 · filed 2 July 2026
- exercised options over 4,183 shares of Contineum Therapeutics (a derivative holding)SEC Form 42 July 2026Stock Option (right to buy) · traded 1 July 2026 · filed 2 July 2026
- ▼ sold on the open market 4,170 shares of Contineum TherapeuticsSEC Form 41 June 2026Class A Common Stock · traded 1 June 2026 · filed 1 June 2026
- ▼ sold on the open market 3,870 shares of Contineum TherapeuticsSEC Form 41 May 2026Class A Common Stock · traded 1 May 2026 · filed 1 May 2026
- ▼ sold on the open market 300 shares of Contineum TherapeuticsSEC Form 41 May 2026Class A Common Stock · traded 1 May 2026 · filed 1 May 2026
- ▼ sold on the open market 4,170 shares of Contineum TherapeuticsSEC Form 46 April 2026Class A Common Stock · traded 6 April 2026 · filed 6 April 2026
- ▼ sold on the open market 4,170 shares of Contineum TherapeuticsSEC Form 42 March 2026Class A Common Stock · traded 2 March 2026 · filed 2 March 2026
- ▼ sold on the open market 4,170 shares of Contineum TherapeuticsSEC Form 42 March 2026Class A Common Stock · traded 2 March 2026 · filed 2 March 2026
- exercised options over 4,300 shares of Contineum TherapeuticsSEC Form 426 February 2026Class A Common Stock · traded 24 February 2026 · filed 26 February 2026
- ▼ sold on the open market 4,300 shares of Contineum TherapeuticsSEC Form 426 February 2026Class A Common Stock · traded 24 February 2026 · filed 26 February 2026
- exercised options over 3,824 shares of Contineum TherapeuticsSEC Form 426 February 2026Class A Common Stock · traded 25 February 2026 · filed 26 February 2026
- exercised options over 4,300 shares of Contineum Therapeutics (a derivative holding)SEC Form 426 February 2026Stock Option (right to buy) · traded 24 February 2026 · filed 26 February 2026
- exercised options over 3,824 shares of Contineum Therapeutics (a derivative holding)SEC Form 426 February 2026Stock Option (right to buy) · traded 25 February 2026 · filed 26 February 2026
- ▼ sold on the open market 3,824 shares of Contineum TherapeuticsSEC Form 426 February 2026Class A Common Stock · traded 25 February 2026 · filed 26 February 2026
- exercised options over 4,300 shares of Contineum Therapeutics (a derivative holding)SEC Form 426 February 2026Stock Option (right to buy) · traded 24 February 2026 · filed 26 February 2026
- exercised options over 3,824 shares of Contineum Therapeutics (a derivative holding)SEC Form 426 February 2026Stock Option (right to buy) · traded 25 February 2026 · filed 26 February 2026
- exercised options over 4,300 shares of Contineum TherapeuticsSEC Form 426 February 2026Class A Common Stock · traded 24 February 2026 · filed 26 February 2026
- ▼ sold on the open market 4,300 shares of Contineum TherapeuticsSEC Form 426 February 2026Class A Common Stock · traded 24 February 2026 · filed 26 February 2026
- exercised options over 3,824 shares of Contineum TherapeuticsSEC Form 426 February 2026Class A Common Stock · traded 25 February 2026 · filed 26 February 2026
- ▼ sold on the open market 3,824 shares of Contineum TherapeuticsSEC Form 426 February 2026Class A Common Stock · traded 25 February 2026 · filed 26 February 2026
- exercised options over 100 shares of Contineum TherapeuticsSEC Form 420 February 2026Class A Common Stock · traded 19 February 2026 · filed 20 February 2026
- ▼ sold on the open market 100 shares of Contineum TherapeuticsSEC Form 420 February 2026Class A Common Stock · traded 19 February 2026 · filed 20 February 2026
- exercised options over 100 shares of Contineum Therapeutics (a derivative holding)SEC Form 420 February 2026Stock Option (right to buy) · traded 19 February 2026 · filed 20 February 2026
- exercised options over 100 shares of Contineum Therapeutics (a derivative holding)SEC Form 420 February 2026Stock Option (right to buy) · traded 19 February 2026 · filed 20 February 2026
- exercised options over 100 shares of Contineum TherapeuticsSEC Form 420 February 2026Class A Common Stock · traded 19 February 2026 · filed 20 February 2026
- ▼ sold on the open market 100 shares of Contineum TherapeuticsSEC Form 420 February 2026Class A Common Stock · traded 19 February 2026 · filed 20 February 2026
- exercised options over 400 shares of Contineum TherapeuticsSEC Form 413 February 2026Class A Common Stock · traded 11 February 2026 · filed 13 February 2026
- ▼ sold on the open market 400 shares of Contineum TherapeuticsSEC Form 413 February 2026Class A Common Stock · traded 11 February 2026 · filed 13 February 2026
- exercised options over 400 shares of Contineum Therapeutics (a derivative holding)SEC Form 413 February 2026Stock Option (right to buy) · traded 11 February 2026 · filed 13 February 2026
- exercised options over 400 shares of Contineum Therapeutics (a derivative holding)SEC Form 413 February 2026Stock Option (right to buy) · traded 11 February 2026 · filed 13 February 2026
- exercised options over 400 shares of Contineum TherapeuticsSEC Form 413 February 2026Class A Common Stock · traded 11 February 2026 · filed 13 February 2026
- ▼ sold on the open market 400 shares of Contineum TherapeuticsSEC Form 413 February 2026Class A Common Stock · traded 11 February 2026 · filed 13 February 2026
- ▼ sold on the open market 3,000 shares of Contineum TherapeuticsSEC Form 45 February 2026Class A Common Stock · traded 3 February 2026 · filed 5 February 2026
- ▼ sold on the open market 1,170 shares of Contineum TherapeuticsSEC Form 45 February 2026Class A Common Stock · traded 3 February 2026 · filed 5 February 2026
- ▼ sold on the open market 3,000 shares of Contineum TherapeuticsSEC Form 45 February 2026Class A Common Stock · traded 3 February 2026 · filed 5 February 2026
- ▼ sold on the open market 1,170 shares of Contineum TherapeuticsSEC Form 45 February 2026Class A Common Stock · traded 3 February 2026 · filed 5 February 2026
- was granted 160,000 shares of Contineum Therapeutics (a derivative holding)SEC Form 430 January 2026Stock Option (right to buy) · traded 30 January 2026 · filed 30 January 2026
- was granted 6,500 shares of Contineum Therapeutics (a derivative holding)SEC Form 430 January 2026Stock Option (right to buy) · traded 30 January 2026 · filed 30 January 2026
- was granted 160,000 shares of Contineum Therapeutics (a derivative holding)SEC Form 430 January 2026Stock Option (right to buy) · traded 30 January 2026 · filed 30 January 2026
- was granted 6,500 shares of Contineum Therapeutics (a derivative holding)SEC Form 430 January 2026Stock Option (right to buy) · traded 30 January 2026 · filed 30 January 2026
- ▼ sold on the open market 3,670 shares of Contineum TherapeuticsSEC Form 46 January 2026Class A Common Stock · traded 5 January 2026 · filed 6 January 2026
- ▼ sold on the open market 500 shares of Contineum TherapeuticsSEC Form 46 January 2026Class A Common Stock · traded 5 January 2026 · filed 6 January 2026
- ▼ sold on the open market 3,670 shares of Contineum TherapeuticsSEC Form 46 January 2026Class A Common Stock · traded 5 January 2026 · filed 6 January 2026
- ▼ sold on the open market 500 shares of Contineum TherapeuticsSEC Form 46 January 2026Class A Common Stock · traded 5 January 2026 · filed 6 January 2026
- ▼ sold on the open market 4,170 shares of Contineum TherapeuticsSEC Form 430 December 2025Class A Common Stock · traded 23 December 2025 · filed 30 December 2025
- was granted 110,000 shares of Contineum Therapeutics (a derivative holding)SEC Form 431 January 2025Stock Option (right to buy) · traded 31 January 2025 · filed 31 January 2025
- was granted 3,700 shares of Contineum Therapeutics (a derivative holding)SEC Form 431 January 2025Stock Option (right to buy) · traded 31 January 2025 · filed 31 January 2025
- ▼ sold on the open market 1,010 shares of Contineum TherapeuticsSEC Form 427 November 2024Class A Common Stock · traded 25 November 2024 · filed 27 November 2024
- ▼ sold on the open market 6,091 shares of Contineum TherapeuticsSEC Form 420 November 2024Class A Common Stock · traded 18 November 2024 · filed 20 November 2024
- ▼ sold on the open market 99 shares of Contineum TherapeuticsSEC Form 420 November 2024Class A Common Stock · traded 18 November 2024 · filed 20 November 2024
- was granted 100,000 shares of Contineum Therapeutics (a derivative holding)SEC Form 429 May 2024Stock Option (right to buy) · traded 24 May 2024 · filed 29 May 2024
- was granted 3,700 shares of Contineum Therapeutics (a derivative holding)SEC Form 429 May 2024Stock Option (right to buy) · traded 24 May 2024 · filed 29 May 2024
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.